ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,269.30
1.01%
Dow Jones
39,935.07
0.00%
Gold vs US Dollar
2,376.63
0.52%
Brent Oil
80.765
-0.94%
Bitcoin
67,365.32
2.40%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Italy
  5. BIT

  6. Biogen Inc (1BIIB) Share Price

1BIIB Biogen Inc

209.00
0.00 (0.00%)
Last Updated: 14:08:02
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Biogen Inc BIT:1BIIB Italian Stock Exchange Ordinary Share  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 209.00 196.90 200.10 0.00 0.00  0.00 13:08:02   
 Type  Size  Price  Time  Units 
   0.00  
 
Recent News
DateTimeSource
HeadlineMore 1BIIB News
26/07/202412:20UKREGUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
02/07/202414:16GLOBEBiogen Completes Acquisition of Human Immunology Biosciences
28/06/202400:39GLOBE“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
24/06/202412:30GLOBETOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
10/06/202400:37GLOBEFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
30/05/202421:51GLOBEBiogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
22/05/202412:30GLOBEBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Period
Draw mode
Data Downloads for 1BIIB

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Biogen Inc Articles